about
Susceptible and protective eNOS haplotypes in hypertensive black and white subjectsEthanol consumption increases blood pressure and alters the responsiveness of the mesenteric vasculature in ratsOmeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteersMedical management of neurocysticercosis.Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis.Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples.Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples.Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers.Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivityPharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis.Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosisTransplacental Distribution of Lidocaine and Its Metabolite in Peridural Anesthesia Administered to Patients With Gestational Diabetes MellitusBusulfan dosing algorithm and sampling strategy in stem cell transplantation patients.Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patientsInfluence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomersAn indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics.Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome.Chronic ethanol intake modulates vascular levels of endothelin-1 receptor and enhances the pressor response to endothelin-1 in anaesthetized rats.Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.Epidural versus intravenous fentanyl for postoperative analgesia following orthopedic surgery: randomized controlled trial.Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS/MS: Application to pharmacokinetics.Pharmacokinetics of nebivolol in the rat: low oral absorption, loss in the gut and systemic stereoselectivity.Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension.Enantioselective analysis of ibuprofen in human plasma by anionic cyclodextrin-modified electrokinetic chromatography.Simultaneous liquid chromatography-tandem mass spectrometric determination of albendazole sulfoxide and albendazole sulfone in plasma.Enantioselective determination of metoprolol acidic metabolite in plasma and urine using liquid chromatography chiral columns: applications to pharmacokinetics.Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus.Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats.Stereoselective metabolism of metoprolol: enantioselectivity of alpha-hydroxymetoprolol in plasma and urine.Determination of paroxetine in geriatric depression by high-performance liquid chromatography.Enantioselective determination of lercanidipine in human plasma for pharmacokinetic studies by normal-phase liquid chromatography-tandem mass spectrometry.Stereoselectivity in the placental transfer and kinetic disposition of racemic bupivacaine administered to parturients with or without a vasoconstrictor.Metoprolol oxidation polymorphism in Brazilian elderly cardiac patients.Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis.Enantioselective kinetic disposition of fenoprofen in rats with experimental diabetes or adjuvant-induced arthritis.Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women.Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen.
P50
Q28272740-E78EE036-4FFD-43C5-A4DD-2EB50A3924EFQ28571631-3AF44614-5876-42D4-A3B5-85FB15B36257Q34019331-88C56F3F-7BAD-4ABF-8C96-624939DFB6D8Q34074147-0EB5D835-DFE6-4718-842A-9232AB721233Q34129452-B906375B-5B9D-4470-B0BD-11B485A3BC39Q34448567-E940E110-89E8-454F-93DE-16D06537FF47Q34461963-DFDC6A68-A4C9-4EAD-8E70-186F05632AE8Q34657726-5D04EFC7-2E3D-4CE4-BE14-4BEED767A913Q34830010-FCBC4115-DFA9-4236-9AE3-281395DB5BC5Q35120602-A4FE6BAE-3CBE-4358-989E-4535A91AA348Q35286070-B6645803-791F-4646-A17B-B5D79372B4FAQ35803978-3B40BCF4-E044-4F28-8C2D-801F3A06087DQ36047153-FFAD4EE2-8C64-4B5C-AA61-DEF8B03F3AE7Q36125427-0A6DA58B-CED6-4F28-8EB7-D91775451E85Q36243677-AF20D27B-C29E-449E-950A-92BF8FCD69E4Q37030741-9C820367-0739-4150-83F3-965B065D46D2Q38756414-F9C8232D-5DB3-4B4C-91A1-08352DFAE1CFQ38776173-9B9CABCB-2513-4D51-86D5-99863E96D4C1Q39754625-77543371-061D-46B1-B848-843D5E0E313AQ39872938-FE56C7D8-226D-42CC-8C2E-8074FEC908C6Q39944445-83D6D16C-DD4E-4C4E-AF3B-78BA37364DAFQ43050418-FBEA7F3C-3848-4614-941D-26BB1DE80018Q43295639-F0B9CACD-1B5A-4E34-B4A2-93FC912C90F8Q43857564-A7A97A1E-4E38-4144-B227-C14F9830F7CAQ43888296-1AFA4846-9753-480B-BB6A-DC445657AB1BQ44069080-CCD43058-2DB9-460C-84DB-795226D25F2CQ44122398-DC54F920-33D9-4C48-AA2E-8A16B6435617Q44228271-3EE0612C-4AA8-4ACE-A12F-0914C78737CCQ44249402-263ECF82-63D2-42F3-9D81-E28651B9F9DAQ44250239-9AC1CD87-B1E4-4885-89D0-AE52B357957FQ44254467-6380F046-690B-46D5-8A3C-CFE199496FBCQ44458311-D3AEF3F3-ED63-4E11-A7D8-3E95BC17DA47Q44473073-4A72746D-7549-4B18-A3BB-BAE0F4927AE7Q44633707-6A63415D-9BCD-4B08-AA68-8C27636CCE01Q44719899-3A6C7BDC-F1AA-4699-9A98-94DF09507E75Q44772582-97C343A3-4F36-481C-B6A0-8DBE5B99ACD9Q45004690-8F94C020-E8E0-4AC1-85CD-3603FD23B3F9Q45032734-0A58AE02-3724-4027-89DD-7388DA948664Q45057673-7FCE47F3-6E54-48FA-A2CB-73C65F0045F1Q45076763-82455A7F-FDF8-4DCC-B96F-09305D729A82
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vera Lucia Lanchote
@ast
Vera Lucia Lanchote
@en
Vera Lucia Lanchote
@es
Vera Lucia Lanchote
@nl
Vera Lucia Lanchote
@sl
type
label
Vera Lucia Lanchote
@ast
Vera Lucia Lanchote
@en
Vera Lucia Lanchote
@es
Vera Lucia Lanchote
@nl
Vera Lucia Lanchote
@sl
prefLabel
Vera Lucia Lanchote
@ast
Vera Lucia Lanchote
@en
Vera Lucia Lanchote
@es
Vera Lucia Lanchote
@nl
Vera Lucia Lanchote
@sl
P106
P21
P31
P496
0000-0002-0074-4953